Abstract
Background
In patients on oral anticoagulation with warfarin, genetic variations of the cytochrome P 450–CYP2C9 have recently been associated with very low warfarin requirements. Patients needing low doses had an increased risk for bleeding complications. In Germany, phenprocoumon (having a similar metabolic pathway) is the most commonly employed vitamin K antagonist. Treatment is usually monitored by general practitioners (GPs).
Objectives
To determine whether CYP2C9 variant alleles can serve as risk markers in general-practice patients anticoagulated with phenprocoumon.
Methods
All adult anticoagulated patients in 12 teaching general practices and one university outpatient clinic were to be recruited. Blood samples were taken from 185 patients during routine anticoagulation controls and tested for CYP2C9 mutations. Subjects answered a questionnaire concerning bleeding complications, drug intolerance, and personal and family medical history. Phenprocoumon dosages required for stable anticoagulation were recorded. Odds ratios (OR) with 95% confidence intervals (CI) were calculated based on 2-way cross-tabulations and multivariate logistic regression models, t-tests used where appropriate.
Results
Bleeding was reported by 19% of the patients, 2.2% of whom had suffered life-threatening bleeding. CYP2C9 variants were carried by 26.3% of 179 patients tested (17.9% *1/*2, 7.8% *1/*3, 0.6% *2/*3). While presence of a *2 allele was not associated with an increased risk (OR 0.35, CI 0.10–1.24), carriers of the rare *3 alleles had a higher risk of bleeding (OR 3.10, CI 1.02–9.40). With regard to bleeding, carrying CYP2C9*3 was highly specific (94%), though sensitivity was low at 17%; post-test probability of bleeding was 40%.
Conclusions
CYP2C9*3 variants are associated with an increased bleeding risk in patients anticoagulated with phenprocoumon. Screening can identify patients with a high risk of bleeding. Appropriate clinical consequences (restricted indication for anticoagulation, careful induction, adjustment of target INR, closer monitoring or self-testing of INR) as well as the cost-effectiveness of screening for variant CYP2C9 with regard to patient outcomes should be subject of further research.
Similar content being viewed by others
References
Kuijer PM, Hutten BA, Prins MH, Buller HR (1999) Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 159:457–460
Schwabe U (2000) Anticoagulants. In: Schwabe U, Paffrath D (eds) Drug prescribing report 2000 [in German]. Springer, Berlin, Heidelberg, pp 186–194
Hirsh J, Ginsberg JS, Marder VJ (1994) Anticoagulant therapy with coumarin agents. In: Colman RW, Hirsh J, Marder VJ, Salzman EW (eds) Hemostasis and thrombosis: basic principles and clinical practice, 3rd edn. Lippincott, Philadelphia, pp 1567–1583
Kristiansen C, Lassen JF, Dahler-Eriksen BS, Dahler-Eriksen K, Larsen TB, Brandslund I (2000) Evaluation of a simple dosage scheme for transition from phenprocoumon to warfarin in oral anticoagulation. Thromb Res 98:157–163
Harder S, Thurmann P (1996) Clinically important drug interactions with anticoagulants. An update. Clin Pharmacokinet 30:416–444
He M, Korzekwa KR, Jones JP, Rettie AE, Trager WF (1999) Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9. Arch Biochem Biophys 372:16–28
Brockmöller J, Kirchheiner J, Meisel C, Roots I (2000) Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment. Pharmacogenomics 1:125–151
Aithal GP, Day CP, Kesteven PJ, Daly AK (1999) Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353:717–719
Margaglione M, Colaizzo D, D'Andrea G et al. (2000) Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 84:775–778
Higashi MK, Veenstra DL, Kondo LM et al. (2002) Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287:1690–1698
Fitzmaurice DA, Hobbs FD, Murray ET (1998) Primary care anticoagulant clinic management using computerized decision support and near patient International Normalized Ratio (INR) testing: routine data from a practice nurse-led clinic. Fam Pract 15:144–146
Hobbs FD, Fitzmaurice DA (1997) Where should oral anticoagulation monitoring take place? Br J Gen Pract 47:479–480
Baglin T (2001) Avoiding overanticoagulation: pharmacogenomics or pragmatism? Thromb Haemost 85:945–946
Holtzman NA, Marteau TM (2001) Will genetics revolutionize medicine? N Engl J Med 343:141–144
Emery J, Hayflick S (2001) The challenge of integrating genetic medicine into primary care. BMJ 322:1027–1030
Wolf CR, Smith G, Smith RL (2000) Science, medicine, and the future: pharmacogenetics. BMJ 320:987–990
Yasar U, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sjoqvist F (1999) Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 254:628–631
Scordo MG, Aklillu E, Yasar U, Dahl ML, Spina E, Ingelman-Sundberg M (2001) Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol 52:447–450
Scottish Intercollegiate Guidelines Network (1999) Antithrombotic therapy. A national clinical guideline. Edinburgh (Scotland). SIGN publication no. 36. http://www.guideline.gov/VIEWS/full_text.asp?guideline=002133 (accessed on 30 December 2002)
Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR (1996) Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 6:429–439
SAS Institute (1999) SAS/STAT. User's guide, version 8, vol 3. SAS Institute, Cary, NC
Sackett DL, Richardson WS, Rosenberg W, Haynes RB (1997) Evidence-based medicine. Churchill Livingstone, New York
Crespi CL, Miller VP (1997) The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Pharmacogenetics 7:203–210
Mannucci PM (1999) Genetic control of anticoagulation. Lancet 353:688–689
Verstuyft C, Morin S, Robert A et al. (2001) Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers. Pharmacogenetics 11:735–737
Halkin H, Lubetsky A (1999) Warfarin dose requirement and CYP2C9 polymorphisms. Lancet 353:1972–1973
Kortke H, Korfer R (2001) International normalized ratio self-management after mechanical heart valve replacement: is an early start advantageous? Ann Thorac Surg 72:44–48
Cromheecke ME, Levi M, Colly LP et al. (2000) Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomized cross-over comparison. Lancet 356:97–102
Walton RT, Harvey E, Dovey S, Freemantle N (2001) Computerised advice on drug dosage to improve prescribing practice. Cochrane Database Syst Rev 1
Bell-Syer SE, Moffett JA (2000) Recruiting patients to randomized trials in primary care: principles and case study. Fam Pract 17:187–191
Wilson S, Delaney BC, Roalfe A et al.(2000) Randomised controlled trials in primary care: case study. BMJ 321:24–27
Beyth RJ (2001) Hemorrhagic complications of oral anticoagulant therapy. Clin Geriatr Med 17:49–56
Akker M van den, Buntinx F, Metsemakers JF, Roos S, Knottnerus JA (1998) Multimorbidity in general practice: prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases. J Clin Epidemiol 51:367–375
Veehof L, Stewart R, Haaijer-Ruskamp F, Jong BM (2000) The development of polypharmacy. A longitudinal study. Fam Pract 17:261–267
Taube J, Halsall D, Baglin T (2000) Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 96:1816–1819
Morin S, Loriot MA, Poirier JM et al. (2000) Is diclofenac a valuable CYP2C9 probe in humans? Eur J Clin Pharmacol 56:793–797
Yasar U, Forslund-Bergengren C, Tybring G et al. (2002) Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther 71:89–98
Acknowledgements
We thank all participating patients and GPs for their cooperation, and Sabine Buth, Susanne Herlt, and Ulrike Lenz for performing the DNA extraction. We are indebted to Prof. Jürgen Brockmöller, Göttingen, and Dr. Robert Walton, Oxford, for critically reviewing the manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hummers-Pradier, E., Hess, S., Adham, I.M. et al. Determination of bleeding risk using genetic markers in patients taking phenprocoumon. Eur J Clin Pharmacol 59, 213–219 (2003). https://doi.org/10.1007/s00228-003-0580-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-003-0580-8